Skip to main content

Table 1 Baseline demographics

From: Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

 

Olaratumab + Liposomal Doxorubicin (n = 62)

Liposomal Doxorubicin (n = 61)

Total (N = 123)

Sex, No. (%)

 Female

62 (100.0)

61 (100.0)

123 (100.0)

Race, No. (%)

 Asian

1 (1.6)

3 (4.9)

4 (3.3)

 Black or African American

5 (8.1)

1 (1.6)

6 (4.9)

 Native Hawaiian or other Pacific Islander

0

1 (1.6)

1 (0.8)

 White

54 (87.1)

54 (88.5)

108 (87.8)

 Other

2 (3.2)

2 (3.3)

4 (3.3)

Ethnicity, No. (%)

 Hispanic or Latino

1 (1.6)

6 (9.8)

7 (5.7)

 Non-Hispanic or Latino

61 (98.4)

54 (88.5)

115 (93.5)

 Missing

0

1 (1.6)

1 (0.8)

Age, yrs

 Mean (SD)

58.7 (10.07)

59.8 (9.70)

59.3 (9.86)

ECOG PS, No. (%)

 0

37 (59.7)

31 (50.8)

68 (55.3)

 1

25 (40.3)

30 (49.2)

55 (44.7)

Prior chemotherapy, No. (%)

62 (100.0)

61 (100.0)

123 (100.0)

Stratification factor (CRF), No. (%)

 Platinum-refractory

13 (21.0)

17 (27.9)

30 (24.4)

 Platinum-resistant

49 (79.0)

44 (72.1)

93 (75.6)

Stratification factor (IVRS), No. (%)

 Platinum-refractory

15 (24.2)

16 (26.2)

31 (25.2)

 Platinum-resistant

47 (75.8)

45 (73.8)

92 (74.8)

  1. CRF case report form, ECOG PS Eastern Cooperative Oncology Group performance status, IVRS interactive voice response system, SD standard deviation, yrs. years